Page 22«..10..21222324..3040..»

Blue Water Vaccines Announces Signing of Sponsored Research Agreement with The University of Texas Health Science Center at San Antonio to Initiate…

By Dr. Matthew Watson

CINCINNATI, April 12, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced the signing of a Sponsored Research Agreement (the “Agreement”) with The University of Texas Health Science Center at San Antonio (“UT Health Science Center San Antonio”) to fund a non-human primate (“NHP”) study to evaluate the efficacy of BWV-401, a live attenuated, orally delivered Chlamydia vaccine.

Read more here:
Blue Water Vaccines Announces Signing of Sponsored Research Agreement with The University of Texas Health Science Center at San Antonio to Initiate...

To Read More: Blue Water Vaccines Announces Signing of Sponsored Research Agreement with The University of Texas Health Science Center at San Antonio to Initiate…
categoriaGlobal News Feed commentoComments Off on Blue Water Vaccines Announces Signing of Sponsored Research Agreement with The University of Texas Health Science Center at San Antonio to Initiate… | dataApril 13th, 2023
Read All

Century Therapeutics Announces Leadership Changes

By Dr. Matthew Watson

– Lalo Flores, Ph.D., steps down as Chief Executive Officer and member of Board of Directors; Greg Russotti, Ph.D., Chief Technology Officer, assumes role of ad-interim Chief Executive Officer –

Read the original post:
Century Therapeutics Announces Leadership Changes

To Read More: Century Therapeutics Announces Leadership Changes
categoriaGlobal News Feed commentoComments Off on Century Therapeutics Announces Leadership Changes | dataApril 13th, 2023
Read All

Tenax Therapeutics Provides 2023 Business Update

By Dr. Matthew Watson

CHAPEL HILL, N.C., April 12, 2023 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today provided a business update outlining the Company’s product development plans for 2023.

Visit link:
Tenax Therapeutics Provides 2023 Business Update

To Read More: Tenax Therapeutics Provides 2023 Business Update
categoriaGlobal News Feed commentoComments Off on Tenax Therapeutics Provides 2023 Business Update | dataApril 13th, 2023
Read All

AIM ImmunoTech Appoints Preeminent Biotechnology Pioneer, W. Neal Burnette, Ph.D., as Chairman of its Scientific Advisory Board (SAB)

By Dr. Matthew Watson

Company’s SAB is comprised of well-established leaders with expertise across biomedical research, academia, and pharmaceutical industry

Read the original:
AIM ImmunoTech Appoints Preeminent Biotechnology Pioneer, W. Neal Burnette, Ph.D., as Chairman of its Scientific Advisory Board (SAB)

To Read More: AIM ImmunoTech Appoints Preeminent Biotechnology Pioneer, W. Neal Burnette, Ph.D., as Chairman of its Scientific Advisory Board (SAB)
categoriaGlobal News Feed commentoComments Off on AIM ImmunoTech Appoints Preeminent Biotechnology Pioneer, W. Neal Burnette, Ph.D., as Chairman of its Scientific Advisory Board (SAB) | dataApril 13th, 2023
Read All

Ceapro Inc. Reports Record 2022 Financial Results and Operational Highlights

By Dr. Matthew Watson

– 2022 marks Ceapro’s best performance in Company history with record sales of $18,800,000 compared to $17,200,000 for 2021, representing a 10% increase year over year

Link:
Ceapro Inc. Reports Record 2022 Financial Results and Operational Highlights

To Read More: Ceapro Inc. Reports Record 2022 Financial Results and Operational Highlights
categoriaGlobal News Feed commentoComments Off on Ceapro Inc. Reports Record 2022 Financial Results and Operational Highlights | dataApril 13th, 2023
Read All

Celularity’s Dr. Robert Hariri To Co-Chair The 2023 International Precision Medicine Center (IPMC) Conference “Beyond Longevity: Live 120 Like…

By Dr. Matthew Watson

Hariri, Celularity’s CEO, Chairman and Founder, will open the meeting with the keynote address highlighting recent progress and important next steps for the science of longevity together with Scott Gottlieb, M.D., Senior Fellow of the American Enterprise Institute and former Commissioner of the U.S. Food and Drug Administration

More:
Celularity’s Dr. Robert Hariri To Co-Chair The 2023 International Precision Medicine Center (IPMC) Conference “Beyond Longevity: Live 120 Like...

To Read More: Celularity’s Dr. Robert Hariri To Co-Chair The 2023 International Precision Medicine Center (IPMC) Conference “Beyond Longevity: Live 120 Like…
categoriaGlobal News Feed commentoComments Off on Celularity’s Dr. Robert Hariri To Co-Chair The 2023 International Precision Medicine Center (IPMC) Conference “Beyond Longevity: Live 120 Like… | dataApril 13th, 2023
Read All

CancerVAX CEO Ryan Davies Discusses Cancer Research with Leading Pediatric Hematologic Oncologist

By Dr. Matthew Watson

Dr. Satiro De Oliveira, a principal investigator in the Company’s cancer research program at UCLA, comments about the importance of cancer immunotherapy Dr. Satiro De Oliveira, a principal investigator in the Company’s cancer research program at UCLA, comments about the importance of cancer immunotherapy

See more here:
CancerVAX CEO Ryan Davies Discusses Cancer Research with Leading Pediatric Hematologic Oncologist

To Read More: CancerVAX CEO Ryan Davies Discusses Cancer Research with Leading Pediatric Hematologic Oncologist
categoriaGlobal News Feed commentoComments Off on CancerVAX CEO Ryan Davies Discusses Cancer Research with Leading Pediatric Hematologic Oncologist | dataApril 13th, 2023
Read All

Zealand Pharma to Participate in 22nd Annual Needham Virtual Healthcare Conference

By Dr. Matthew Watson

Press release – No. 2 / 2023

See the rest here:
Zealand Pharma to Participate in 22nd Annual Needham Virtual Healthcare Conference

To Read More: Zealand Pharma to Participate in 22nd Annual Needham Virtual Healthcare Conference
categoriaGlobal News Feed commentoComments Off on Zealand Pharma to Participate in 22nd Annual Needham Virtual Healthcare Conference | dataApril 13th, 2023
Read All

AB Science: Results of masitinib in ALS selected for a scientific platform presentation at the AAN 2023, including long-term survival analysis and a…

By Dr. Matthew Watson

Read this article:
AB Science: Results of masitinib in ALS selected for a scientific platform presentation at the AAN 2023, including long-term survival analysis and a...

To Read More: AB Science: Results of masitinib in ALS selected for a scientific platform presentation at the AAN 2023, including long-term survival analysis and a…
categoriaGlobal News Feed commentoComments Off on AB Science: Results of masitinib in ALS selected for a scientific platform presentation at the AAN 2023, including long-term survival analysis and a… | dataApril 13th, 2023
Read All

 Monthly information related to total number of voting rights and shares composing the share capital _March 31, 2023

By Dr. Matthew Watson

Monthly information related to total number of voting rights and shares composing the share capital _March 31, 2023.

Read the original post:
 Monthly information related to total number of voting rights and shares composing the share capital _March 31, 2023

To Read More:  Monthly information related to total number of voting rights and shares composing the share capital _March 31, 2023
categoriaGlobal News Feed commentoComments Off on  Monthly information related to total number of voting rights and shares composing the share capital _March 31, 2023 | dataApril 13th, 2023
Read All

Optinose to Present at the Needham Virtual Healthcare Conference

By Dr. Matthew Watson

YARDLEY, Pa., April 12, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the Needham Virtual Healthcare Conference on April 17, 2023 at 3:45 p.m. ET.

More:
Optinose to Present at the Needham Virtual Healthcare Conference

To Read More: Optinose to Present at the Needham Virtual Healthcare Conference
categoriaGlobal News Feed commentoComments Off on Optinose to Present at the Needham Virtual Healthcare Conference | dataApril 13th, 2023
Read All

Impel Pharmaceuticals Announces Appointment of Darren Cline to the Board of Directors

By Dr. Matthew Watson

H. Stewart Parker Departing from Board H. Stewart Parker Departing from Board

See the rest here:
Impel Pharmaceuticals Announces Appointment of Darren Cline to the Board of Directors

To Read More: Impel Pharmaceuticals Announces Appointment of Darren Cline to the Board of Directors
categoriaGlobal News Feed commentoComments Off on Impel Pharmaceuticals Announces Appointment of Darren Cline to the Board of Directors | dataApril 13th, 2023
Read All

MedAvail to Report Fourth Quarter and Full Year 2022 Financial Results on April 13

By Dr. Matthew Watson

Management to host investor conference call and webcast at 4:30pm EDT on that day Management to host investor conference call and webcast at 4:30pm EDT on that day

View original post here:
MedAvail to Report Fourth Quarter and Full Year 2022 Financial Results on April 13

To Read More: MedAvail to Report Fourth Quarter and Full Year 2022 Financial Results on April 13
categoriaGlobal News Feed commentoComments Off on MedAvail to Report Fourth Quarter and Full Year 2022 Financial Results on April 13 | dataApril 13th, 2023
Read All

Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference

By Dr. Matthew Watson

CAMBRIDGE, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the 22nd Annual Needham Virtual Healthcare Conference to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Scott Barrett, M.D., Chief Medical Officer, Brett Hall, Ph.D., Chief Scientific Officer, and Mallory Morales, CPA, Vice President of Finance, Treasurer.

Read the original here:
Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference

To Read More: Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference
categoriaGlobal News Feed commentoComments Off on Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference | dataApril 13th, 2023
Read All

Sana Biotechnology Announces Preclinical Data Published in Science Translational Medicine Showing its Hypoimmune Pancreatic Islet Cells Evaded…

By Dr. Matthew Watson

Hypoimmune human islet cells normalized glucose in diabetic humanized immunocompetent mouse model and avoided allogeneic and autoimmune rejection by the immune system

Excerpt from:
Sana Biotechnology Announces Preclinical Data Published in Science Translational Medicine Showing its Hypoimmune Pancreatic Islet Cells Evaded...

To Read More: Sana Biotechnology Announces Preclinical Data Published in Science Translational Medicine Showing its Hypoimmune Pancreatic Islet Cells Evaded…
categoriaGlobal News Feed commentoComments Off on Sana Biotechnology Announces Preclinical Data Published in Science Translational Medicine Showing its Hypoimmune Pancreatic Islet Cells Evaded… | dataApril 13th, 2023
Read All

Vallon Pharmaceuticals Adjourns Special Meeting of Stockholders Until April 20, 2023

By Dr. Matthew Watson

Board of Directors unanimously recommend Vallon stockholders to vote “FOR” all proposals outlined in the Company’s definitive Proxy Statement (the “Proxy”) in order to close the proposed merger with GRI Bio, Inc.

Excerpt from:
Vallon Pharmaceuticals Adjourns Special Meeting of Stockholders Until April 20, 2023

To Read More: Vallon Pharmaceuticals Adjourns Special Meeting of Stockholders Until April 20, 2023
categoriaGlobal News Feed commentoComments Off on Vallon Pharmaceuticals Adjourns Special Meeting of Stockholders Until April 20, 2023 | dataApril 13th, 2023
Read All

DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting

By Dr. Matthew Watson

Montrouge, France, April 12, 2023

Link:
DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting

To Read More: DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting
categoriaGlobal News Feed commentoComments Off on DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting | dataApril 13th, 2023
Read All

Cronos Bolsters its Spinach® Infused Pre-roll Portfolio with CBG, CBC and CBN

By Dr. Matthew Watson

Spinach® rose to 8th place in the pre-roll category, capturing 2.5% market share in Q1 2023, up from 1.4% in Q4 20221

More:
Cronos Bolsters its Spinach® Infused Pre-roll Portfolio with CBG, CBC and CBN

To Read More: Cronos Bolsters its Spinach® Infused Pre-roll Portfolio with CBG, CBC and CBN
categoriaGlobal News Feed commentoComments Off on Cronos Bolsters its Spinach® Infused Pre-roll Portfolio with CBG, CBC and CBN | dataApril 13th, 2023
Read All

Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2023 Spring Clinical…

By Dr. Matthew Watson

Three posters support the important role that XPHOZAH, a novel phosphate absorption inhibitor, could potentially play in the treatment of hyperphosphatemia

Go here to see the original:
Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2023 Spring Clinical...

To Read More: Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2023 Spring Clinical…
categoriaGlobal News Feed commentoComments Off on Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2023 Spring Clinical… | dataApril 13th, 2023
Read All

Nkarta to Participate at Upcoming Investor Conferences

By Dr. Matthew Watson

SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at two upcoming investor conferences:

Continue reading here:
Nkarta to Participate at Upcoming Investor Conferences

To Read More: Nkarta to Participate at Upcoming Investor Conferences
categoriaGlobal News Feed commentoComments Off on Nkarta to Participate at Upcoming Investor Conferences | dataApril 13th, 2023
Read All

Page 22«..10..21222324..3040..»


Copyright :: 2024